VTRS Viatris Inc. - Common Stock
$16,18
Preço · Ago 20, 2026
Fundamentais a partir de Ago 6, 2026
Intervalo 52 Semanas
$9–$18
75% of range
Classificação do Analista
BUY
17 analysts
Preço-Alvo
$18
+14% upside
P/E (TTM)
-4.2
ROE
-23.2%
Margem de Lucro Líquido
-24.6%
Sobre Viatris Inc. - Common Stock Visão geral da empresa da Wikipedia
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Ler mais
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies.
History
On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. At that time, Michael Goettler became chief executive officer. Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS. In December 2020, the company announced a cost-reducing restructuring plan that would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world.
In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. The transaction was completed in November 2022. In November 2022, the business agreed to acquire Oyster Point Pharma and Famy Life Sciences for an aggregate of $700–750 million to create an ophthalmology division. The acquisitions closed in January 2023.
In 2022 and 2024, Viatris was recognized by Forbes as one of the world's best employers and by Newsweek as one of America's most responsible companies. On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, and one of the 25 best companies offering career development in Ireland. In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.
In late December 2024, Viatris disclosed that the U.S. FDA had issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the warning letter is lifted, while four products were conditionally exempted due to shortages. The violations cited by the FDA included subpar quality control and improper management of manufacturing defect. In response, the company announced that it has taken corrective and preventative actions.
Predecessors
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
Products
The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients. Viatris products cover therapeutic areas including cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.
The following products have been newly launched or received regulatory approvals since Viatris was established include:
Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.
Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.
GA Depot (long-acting version of glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.
Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.
Ryzumvi (phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.
Partnerships
Following the formation of Viatris, the company became a member of the Biosimilars Forum, a trade organization that advocates for greater biosimilar usage. Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world.
In December 2020, the company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic. In April 2021, the company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%.
In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
VTRS Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$16.18
Capitalização de Mercado
—
P/E (TTM)
-4.2
EPS (TTM)
$-3.00
Receita (TTM)
$14.30B
Rendimento div.
—
ROE
-23.2%
Dívida/Capital
1.0
Intervalo 52 Semanas
$9 – $18
VTRS Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$14.30B
2018-12-31
→
2025-12-31
EPS
$-3.00
2018-12-31
→
2025-12-31
Fluxo de caixa livre
$1.94B
2025-12-31
→
2025-12-31
Margens
-24.6%
2025-12-31
→
2025-12-31
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
VTRS
Mediana de Pares
P/E (TTM)
-4.2
32.1
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
VTRS
Mediana de Pares
Gross Margin (Margem Bruta)
35.1%
71.8%
Operating Margin (Margem Operacional)
-18.6%
—
Net Profit Margin (Margem de Lucro Líquido)
-24.6%
13.0%
ROA
-8.9%
6.4%
ROE
-23.2%
15.1%
ROIC
-8.8%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
VTRS
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
1.0
—
Current Ratio (Índice de liquidez corrente)
1.4
1.6
Quick Ratio (Índice de Liquidez Seca)
0.6
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
VTRS
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
-3.0%
—
Revenue CAGR 3Y (CAGR Receita 3A)
-4.2%
—
Revenue CAGR 5Y (CAGR Receita 5A)
3.7%
—
EPS YoY
-97.1%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-97.4%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
VTRS
Mediana de Pares
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
Dividend Yield
—
Índice de Pagamento
—
CAGR Dividendos 5 anos
—
| Data ex | Valor |
|---|---|
| 22 de Maio de 2026 | $0,1200 |
| 9 de Março de 2026 | $0,1200 |
| 24 de Novembro de 2025 | $0,1200 |
| 22 de Agosto de 2025 | $0,1200 |
| 23 de Maio de 2025 | $0,1200 |
| 10 de Março de 2025 | $0,1200 |
| 22 de Novembro de 2024 | $0,1200 |
| 23 de Agosto de 2024 | $0,1200 |
| 23 de Maio de 2024 | $0,1200 |
| 8 de Março de 2024 | $0,1200 |
| 22 de Novembro de 2023 | $0,1200 |
| 23 de Agosto de 2023 | $0,1200 |
| 23 de Maio de 2023 | $0,1200 |
| 8 de Março de 2023 | $0,1200 |
| 22 de Novembro de 2022 | $0,1200 |
| 23 de Agosto de 2022 | $0,1200 |
| 23 de Maio de 2022 | $0,1200 |
| 23 de Fevereiro de 2022 | $0,1200 |
| 22 de Novembro de 2021 | $0,1100 |
| 23 de Agosto de 2021 | $0,1100 |
VTRS Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
17 analistas
- Compra forte 4 23,5%
- Compra 7 41,2%
- Manter 5 29,4%
- Venda 1 5,9%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
8 analistas · 2026-08-19
Mediana
$19.00
Agora
$16.18
Mín
$12.00
Máx
$23.00
Alvo mediano
$19.00
+17,4%
Alvo médio
$18.50
+14,3%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.05%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.69 | $0.61 | 0.08% |
| 31 de Março de 2026 | $0.59 | $0.51 | 0.08% |
| 31 de Dezembro de 2025 | $0.57 | $0.54 | 0.03% |
| 30 de Setembro de 2025 | $0.67 | $0.63 | 0.04% |
| 30 de Junho de 2025 | $0.62 | $0.57 | 0.05% |
| 31 de Março de 2025 | $0.50 | $0.50 | 0.00% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | $11.43B | |
| Cost of Revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B | $7.60B | $7.43B | |
| Gross Profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B | $3.90B | $4.00B | |
| R&D Expense | · | · | · | · | $751M | $555M | $640M | $704M | |
| SG&A Expense | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B | $3.34B | $2.56B | $2.44B | |
| Operating Expenses | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B | $4.01B | $3.18B | $3.10B | |
| Operating Income | $-2.66B | $10M | $766M | $1.61B | $-34M | $-211M | $716M | $906M | |
| Interest Expense | $471M | $550M | $573M | $592M | $636M | $498M | $517M | $542M | |
| Other Non-op | $-531M | $-83M | $10M | $1.79B | $6M | $-13M | $-44M | $-65M | |
| Pretax Income | $-3.67B | $-623M | $203M | $2.81B | $-664M | $-721M | $154M | $298M | |
| Income Tax | $-150M | $11M | $148M | $735M | $605M | $-51M | $138M | $-54M | |
| Net Income | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | $352M | |
| EPS (Basic) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.69 | |
| EPS (Diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 | |
| Shares (Basic) | · | · | 1,200,300,000 | 1,212,100,000 | 1,208,800,000 | 601,200,000 | 515,700,000 | 514,500,000 | |
| Shares (Diluted) | · | · | 1,206,900,000 | 1,217,400,000 | 1,208,800,000 | 601,200,000 | 516,500,000 | 516,500,000 | |
| EBITDA | $135M | · | · | · | · | · | · | · |
Balanço Patrimonial 30
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.32B | $735M | $992M | $1.26B | $701M | $844M | $476M | $388M | |
| Short-term Investments | · | · | · | · | · | $39M | $27M | · | |
| Receivables | $3.03B | $3.22B | $3.70B | $3.81B | $4.27B | $4.84B | $3.06B | · | |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | $3.98B | $5.47B | $2.67B | · | |
| Prepaid Expense | $1.44B | $1.71B | $2.03B | $1.81B | $1.96B | $1.71B | $552M | · | |
| Other Current Assets | $136M | $387M | $271M | $328M | $1.47B | $1.24B | $286M | · | |
| Current Assets | $9.79B | $9.52B | $12.98B | $10.64B | $10.90B | $12.87B | $6.76B | · | |
| PP&E (Net) | $2.61B | $2.67B | $2.76B | $3.02B | $3.19B | $3.46B | $2.15B | · | |
| PP&E (Gross) | $5.13B | $4.87B | $4.77B | $5.08B | $5.59B | $5.72B | $4.12B | · | |
| Accum. Depreciation | $2.52B | $2.20B | $2.01B | $2.06B | $2.40B | $2.26B | $1.97B | · | |
| Goodwill | $6.75B | $9.13B | $9.87B | $10.43B | $12.11B | $12.35B | $9.59B | $9.75B | |
| Intangibles | $15.10B | $17.07B | $19.18B | $22.61B | $26.13B | $29.68B | $11.65B | · | |
| Other Non-current Assets | $1.87B | $2.36B | $2.21B | $2.40B | $1.17B | $1.05B | $405M | · | |
| Total Assets | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Short-term Debt | · | · | · | $0 | $1.49B | $1.10B | $0 | · | |
| Current Liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B | $10.56B | $5.57B | · | |
| Capital Leases | $178M | $179M | $165M | $181M | $201M | $230M | $176M | · | |
| Deferred Tax | $892M | $1.11B | $1.74B | $2.43B | $2.81B | $3.12B | $1.63B | · | |
| Other Non-current Liabilities | $2.01B | $1.94B | $1.52B | $1.76B | $1.93B | $2.48B | $961M | · | |
| Total Liabilities | $22.48B | $22.87B | $27.22B | $28.95B | $34.35B | $38.60B | $19.37B | · | |
| Long-term Debt | $14.41B | $14.05B | $18.13B | $19.27B | $21.59B | $24.74B | $12.72B | · | |
| Total Debt | $14.41B | · | · | · | · | · | · | · | |
| Common Stock | $12M | $12M | $12M | $12M | $12M | $12M | $6M | · | |
| Paid-in Capital | $18.80B | $18.92B | $18.81B | $18.65B | $18.54B | $18.44B | $8.64B | · | |
| Retained Earnings | $-388M | $3.42B | $4.64B | $5.18B | $3.69B | $5.36B | $6.03B | · | |
| Treasury Stock | $1.01B | $504M | $252M | $0 | $0 | $0 | $1000M | · | |
| AOCI | $-2.71B | $-3.21B | $-2.75B | $-2.76B | $-1.74B | $-858M | $-1.80B | · | |
| Stockholders' Equity | $14.71B | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B | $11.88B | $12.17B | |
| Liabilities + Equity | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Shares Outstanding | · | · | · | · | · | · | 100 | · |
Fluxo de Caixa 19
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.80B | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B | $2.02B | $2.11B | |
| Stock-based Comp | $178M | $146M | $181M | $116M | $111M | $79M | $57M | $-3M | |
| Deferred Tax | $-476M | $-768M | $-387M | $-26M | $676M | $-213M | $-193M | $-264M | |
| Amort. of Intangibles | $2.35B | $2.35B | $2.32B | $2.50B | $2.70B | $1.61B | $1.58B | $1.61B | |
| Restructuring | · | · | · | · | $50M | $50M | $105M | · | |
| Other Non-cash | $3.33B | · | · | · | · | · | · | · | |
| Operating Cash Flow | $2.32B | $2.30B | $2.90B | $3.00B | $3.02B | $1.23B | $1.80B | $2.34B | |
| CapEx | $379M | $326M | $377M | $406M | $457M | $243M | $213M | $252M | |
| Investing Cash Flow | $-428M | $1.80B | $-864M | $1.47B | $-118M | $-301M | $-525M | $-1.21B | |
| Debt Issued | $0 | $0 | $300.0K | $1.88B | $1.71B | $983M | $7M | $2.58B | |
| Net Debt Issued | $-100.0K | · | · | · | · | · | · | · | |
| Stock Issued | $3M | $2M | $3M | $3M | $0 | $0 | · | · | |
| Stock Repurchased | $500M | $250M | $250M | $0 | $0 | $0 | $0 | $432M | |
| Net Stock Activity | $-498M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.29B | $-4.33B | $-2.30B | $-3.88B | $-3.01B | $-606M | $-1.17B | $-1.09B | |
| Net Change in Cash | $612M | $-258M | $-269M | $556M | $-144M | $359M | $102M | $19M | |
| Taxes Paid | $445M | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.94B | · | · | · | · | · | · | · | |
| Levered FCF | $1.49B | · | · | · | · | · | · | · |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.1% | · | · | · | · | · | · | · | |
| Operating Margin | -18.6% | · | · | · | · | · | · | · | |
| Net Margin | -24.6% | · | · | · | · | · | · | · | |
| Pretax Margin | -25.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | 0.95% | · | · | · | · | · | · | · | |
| ROA | -8.9% | · | · | · | · | · | · | · | |
| ROE | -23.2% | · | · | · | · | · | · | · | |
| ROIC | -8.8% | · | · | · | · | · | · | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | · | · | · | · | · | · | · | |
| Quick Ratio | 0.6 | · | · | · | · | · | · | · | |
| Debt / Equity | 1.0 | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.8 | · | · | · | · | · | · | · | |
| Interest Coverage | -5.7 | · | · | · | · | · | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | · | · | · | · | · | · | · | |
| Inventory Turnover | 2.4 | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.6 | · | · | · | · | · | · | · |
Taxas de Crescimento 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -3.0% | -4.5% | -5.1% | -9.1% | 49.7% | · | · | · | |
| Revenue CAGR 3Y | -4.2% | -6.2% | 8.9% | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.7% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | -97.1% | · | · | · | · | · | |
| Net Income YoY | · | · | -97.4% | · | · | · | · | · |
Avaliação (TTM) 6
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | · | |
| Net Income TTM | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | · | |
| Market Cap | · | · | · | · | · | · | $2.0K | · | |
| P/E | -4.2 | -23.5 | 216.6 | 6.5 | -12.9 | -16.9 | 670.0 | · | |
| P/S | · | · | · | · | · | · | 0.0 | · | |
| Earnings Yield | -24.1% | -4.3% | 0.46% | 15.4% | -7.8% | -5.9% | 0.15% | · |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.76B | $3.52B | $3.70B | $3.76B | $3.58B | $3.25B | $3.53B | $3.75B | $3.80B | $3.66B | $3.84B | $3.94B | $3.92B | $3.73B | $3.88B | $4.08B | |
| Cost of Revenue | $2.30B | $2.36B | $2.56B | $2.39B | $2.25B | $2.09B | $2.31B | $2.29B | $2.35B | $2.16B | $2.24B | $2.25B | $2.31B | $2.19B | $2.60B | $2.33B | |
| Gross Profit | $1.46B | $1.16B | $1.15B | $1.37B | $1.33B | $1.16B | $1.22B | $1.46B | $1.45B | $1.50B | $1.60B | $1.69B | $1.61B | $1.54B | $1.27B | $1.75B | |
| R&D Expense | $248M | $249M | · | $250M | $219M | $222M | · | $198M | $204M | $200M | · | $211M | $208M | $183M | · | $175M | |
| SG&A Expense | $1.13B | $929M | $1.03B | $887M | $929M | $948M | $1.05B | $1.00B | $1.04B | $1.02B | $1.03B | $1.05B | $1.03B | $959M | $1.27B | $1.02B | |
| Operating Expenses | $1.45B | $1.24B | $1.34B | $1.19B | $1.10B | $4.04B | $1.39B | $1.23B | $1.69B | $1.30B | $2.05B | $1.24B | $1.24B | $1.14B | $1.48B | $1.19B | |
| Operating Income | $6M | $-80M | $-193M | $179M | $233M | $-2.88B | $-180M | $226M | $-240M | $204M | $-454M | $452M | $369M | $400M | $-201M | $560M | |
| Interest Expense | $121M | $120M | $120M | $120M | $117M | $116M | $120M | $146M | $146M | $138M | $141M | $142M | $144M | $147M | $147M | $153M | |
| Other Non-op | $50M | $-48M | $-31M | $-67M | $-334M | $-99M | $-226M | $10M | $-6M | $139M | $-260M | $92M | $108M | $70M | $1.82B | $21M | |
| Pretax Income | $-64M | $-247M | $-343M | $-8M | $-217M | $-3.10B | $-526M | $90M | $-392M | $205M | $-855M | $402M | $333M | $323M | $1.47B | $428M | |
| Income Tax | $55M | $-424M | $-3M | $120M | $-212M | $-55M | $-10M | $-4M | $-65M | $91M | $-89M | $71M | $69M | $98M | $458M | $73M | |
| EPS (Basic) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.44 | $0.08 | $-0.27 | $0.10 | $-0.64 | $0.28 | $0.22 | $0.19 | $0.83 | $0.29 | |
| EPS (Diluted) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.43 | $0.08 | $-0.27 | $0.09 | $-0.63 | $0.27 | $0.22 | $0.19 | $0.83 | $0.29 | |
| Shares (Basic) | 1,163,300,000 | 1,155,400,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,193,500,000 | 1,191,100,000 | 1,195,200,000 | -2,400,700,000 | 1,199,500,000 | 1,199,000,000 | 1,202,500,000 | -2,423,200,000 | 1,212,500,000 | |
| Shares (Diluted) | 1,163,300,000 | 1,175,300,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,200,400,000 | 1,191,100,000 | 1,209,500,000 | -2,409,800,000 | 1,207,600,000 | 1,203,500,000 | 1,205,600,000 | -2,430,900,000 | 1,218,100,000 | |
| EBITDA | $6M | $596M | · | $179M | $233M | $-2.22B | · | $226M | $-240M | $895M | · | $452M | $369M | $1.13B | · | $560M |
Balanço Patrimonial 28
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $886M | $1.80B | $1.32B | $975M | $566M | $755M | $735M | $1.88B | $917M | $1.01B | $992M | $1.31B | $629M | $507M | $1.26B | $647M | |
| Receivables | $3.13B | $3.08B | $3.03B | $3.37B | $3.26B | $3.13B | $3.22B | $3.72B | $3.57B | $3.63B | · | $3.74B | $3.61B | $3.50B | · | $3.33B | |
| Inventory | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | $4.10B | $3.85B | $4.08B | $3.94B | $3.82B | · | $3.67B | $3.64B | $3.66B | · | $3.38B | |
| Prepaid Expense | $2.11B | $2.11B | $1.44B | $1.49B | $1.69B | $1.65B | $1.71B | $1.63B | $1.76B | $1.93B | · | $1.78B | $1.73B | $1.76B | · | $1.70B | |
| Other Current Assets | $140M | $98M | $136M | $251M | $259M | $355M | $387M | $335M | $270M | $250M | · | $1.20B | $1.18B | $1.35B | · | $1.13B | |
| Current Assets | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | $9.62B | $9.52B | $11.31B | $11.79B | $12.92B | · | $10.93B | $9.78B | $9.63B | · | $10.49B | |
| PP&E (Net) | $2.44B | $2.53B | $2.61B | $2.63B | $2.64B | $2.64B | $2.67B | $2.68B | $2.66B | $2.71B | · | $2.93B | $2.98B | $3.01B | · | $3.04B | |
| PP&E (Gross) | $5.11B | $5.11B | $5.13B | $5.11B | $5.07B | $4.94B | $4.87B | $4.88B | $4.71B | $4.71B | · | $5.04B | $5.05B | $5.15B | · | $5.02B | |
| Accum. Depreciation | $2.67B | $2.58B | $2.52B | $2.48B | $2.42B | $2.30B | $2.20B | $2.21B | $2.05B | $2.00B | · | $2.11B | $2.06B | $2.14B | · | $1.98B | |
| Goodwill | $6.65B | $6.69B | $6.75B | $6.73B | $6.75B | $6.46B | $9.13B | $9.56B | $9.33B | $9.69B | $9.87B | $10.28B | $10.53B | $10.57B | $10.43B | $10.05B | |
| Intangibles | $13.68B | $14.48B | $15.10B | $15.72B | $16.32B | $16.66B | $17.07B | $17.98B | $18.42B | $19.13B | · | $21.28B | $22.08B | $22.70B | · | $23.01B | |
| Other Non-current Assets | $1.06B | $1.11B | $1.87B | $1.89B | $2.00B | $2.27B | $2.36B | $2.47B | $2.45B | $2.23B | · | $2.40B | $2.35B | $2.42B | · | $964M | |
| Total Assets | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $23M | $205M | · | $500M | |
| Current Liabilities | $6.35B | $6.81B | $7.09B | $7.36B | $7.13B | $5.72B | $5.78B | $7.51B | $7.71B | $7.76B | · | $6.83B | $6.52B | $6.11B | · | $6.52B | |
| Capital Leases | $160M | $167M | $178M | $171M | $182M | $177M | $179M | $188M | $192M | $156M | · | $160M | $167M | $173M | · | $179M | |
| Deferred Tax | $803M | $871M | $892M | $1.03B | $1.08B | $1.08B | $1.11B | $1.28B | $1.57B | $1.67B | · | $2.32B | $2.41B | $2.46B | · | $2.49B | |
| Other Non-current Liabilities | $2.02B | $2.08B | $2.01B | $1.82B | $1.84B | $1.84B | $1.94B | $1.87B | $1.80B | $1.83B | · | $1.65B | $1.67B | $1.72B | · | $1.75B | |
| Total Liabilities | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | $22.82B | $22.87B | $24.96B | $25.81B | $27.33B | · | $27.88B | $27.85B | $28.36B | · | $29.48B | |
| Long-term Debt | $13.35B | $14.34B | $14.41B | $14.44B | $14.47B | $14.19B | $14.05B | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.58B | $18.58B | · | $19.49B | |
| Total Debt | $13.35B | $14.34B | · | $14.44B | $14.47B | $14.19B | · | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.60B | $18.78B | · | $19.99B | |
| Common Stock | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Paid-in Capital | $18.56B | $18.66B | $18.80B | $18.89B | $19.00B | $18.96B | $18.92B | $18.89B | $18.85B | $18.84B | · | $18.76B | $18.72B | $18.68B | · | $18.62B | |
| Retained Earnings | $-331M | $-212M | $-388M | $-48M | $80M | $228M | $3.42B | $4.08B | $4.13B | $4.61B | · | $5.55B | $5.37B | $5.25B | · | $4.31B | |
| Treasury Stock | $1.16B | $1.01B | $1.01B | $924M | $856M | $680M | $504M | $504M | $504M | $504M | · | $252M | $252M | $252M | · | · | |
| AOCI | $-2.82B | $-2.80B | $-2.71B | $-2.71B | $-2.66B | $-2.87B | · | $-2.69B | $-2.98B | $-2.94B | · | $-3.21B | $-3.01B | $-2.76B | · | $-3.76B | |
| Stockholders' Equity | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | $15.65B | $18.64B | $19.79B | $19.52B | $20.01B | $20.47B | $20.87B | $20.84B | $20.93B | $21.07B | $19.18B | |
| Liabilities + Equity | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B |
Fluxo de Caixa 17
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $672M | $676M | $767M | $688M | $678M | $665M | $746M | $670M | $786M | $691M | $644M | $679M | $687M | $730M | $870M | $700M | |
| Stock-based Comp | $39M | $48M | $49M | $36M | $37M | $55M | $32M | $32M | $35M | $47M | $56M | $43M | $39M | $43M | $30M | $29M | |
| Deferred Tax | $-124M | $-70M | $-248M | $-137M | $-48M | $-44M | $-249M | $-312M | $-154M | $-52M | $-207M | $-85M | $-68M | $-27M | $154M | $-22M | |
| Amort. of Intangibles | $572M | $585M | $602M | $593M | $583M | $571M | $579M | $575M | $597M | $601M | $539M | $584M | $591M | $603M | $606M | $616M | |
| Restructuring | $27M | $78M | · | · | · | · | · | · | · | · | · | $15M | $74M | $10M | · | $15M | |
| Operating Cash Flow | $382M | $388M | $816M | $745M | $220M | $536M | $483M | $826M | $379M | $615M | $568M | $845M | $525M | $971M | $189M | $869M | |
| CapEx | $53M | $40M | $196M | $87M | $53M | $43M | $140M | $77M | $59M | $50M | $166M | $96M | $68M | $48M | $154M | $104M | |
| Investing Cash Flow | $-52M | $277M | $-211M | $-99M | $-52M | $-65M | $-169M | $1.75B | $376M | $-154M | $27M | $-65M | $-87M | $-750M | $1.74B | $-115M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | $300.0K | $0 | $0 | $0 | $100.0K | $1.08B | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-750M | · | · | |
| Stock Issued | $700.0K | $500.0K | $600.0K | $700.0K | $700.0K | $600.0K | $600.0K | $600.0K | $700.0K | $600.0K | $600.0K | $800.0K | $800.0K | $900.0K | $800.0K | $2M | |
| Stock Repurchased | $150M | $0 | $82M | $68M | $175M | $175M | $0 | $0 | $0 | $250M | $0 | $0 | $0 | $250M | $0 | $0 | |
| Net Stock Activity | · | $500.0K | · | $-68M | $-175M | $-175M | · | · | · | $-249M | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-1.24B | $-204M | $-236M | $-228M | $-362M | $-467M | $-1.42B | $-1.64B | $-848M | $-426M | $-926M | $-98M | $-304M | $-975M | $-1.33B | $-759M | |
| Net Change in Cash | $-916M | $458M | $344M | $436M | $-188M | $20M | $-1.14B | $962M | $-97M | $22M | $-318M | $680M | $121M | $-752M | $612M | $-19M | |
| Free Cash Flow | · | $348M | · | · | · | $493M | · | · | · | $565M | · | · | · | $923M | · | · | |
| Levered FCF | · | $434M | · | · | · | $379M | · | · | · | $488M | · | · | · | $821M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 32.9% | · | 36.5% | 37.2% | 35.7% | · | 38.9% | 38.1% | 41.0% | · | 42.9% | 41.0% | 41.4% | · | 42.9% | |
| Operating Margin | 0.17% | -2.3% | · | 4.8% | 6.5% | -88.6% | · | 6.0% | -6.3% | 5.6% | · | 11.5% | 9.4% | 10.7% | · | 13.7% | |
| Pretax Margin | -1.7% | -7.0% | · | -0.21% | -6.1% | -95.2% | · | 2.4% | -10.3% | 5.6% | · | 10.2% | 8.5% | 8.6% | · | 10.5% | |
| EBITDA Margin | 0.17% | 17.0% | · | 4.8% | 6.5% | -68.1% | · | 6.0% | -6.3% | 24.4% | · | 11.5% | 9.4% | 30.3% | · | 13.7% | |
| ROIC | 0.04% | 0.20% | · | 9.8% | 0.02% | -9.5% | · | 0.67% | -0.55% | 0.30% | · | 0.95% | 0.74% | 0.70% | · | 1.2% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.6 | · | 1.4 | 1.4 | 1.7 | · | 1.5 | 1.5 | 1.7 | · | 1.6 | 1.5 | 1.6 | · | 1.6 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.5 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.7 | 0.6 | 0.7 | · | 0.6 | |
| Debt / Equity | 0.9 | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | |
| LT Debt / Equity | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Interest Coverage | 0.1 | -0.7 | · | 1.5 | 2.0 | -25.0 | · | 1.6 | -1.6 | 1.5 | · | 3.2 | 2.6 | 2.7 | · | 3.7 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.1 | · | 1.1 | 1.0 | 1.0 | · | 1.0 | 1.1 | 1.0 | · | 1.1 | 1.1 | 1.0 | · | 1.1 |
Avaliação (TTM) 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.62B | $14.11B | · | $14.35B | $14.38B | $14.47B | · | $15.15B | $15.32B | $15.25B | · | $15.67B | $15.84B | $16.12B | · | $16.92B | |
| Net Income TTM | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | |
| P/E | -264.7 | -5.4 | · | -3.8 | -3.3 | -3.3 | · | 68.3 | 34.3 | 15.5 | · | 10.2 | 10.4 | 9.0 | · | 7.5 | |
| Earnings Yield | -0.38% | -18.6% | · | -26.1% | -30.7% | -30.4% | · | 1.5% | 2.9% | 6.5% | · | 9.8% | 9.6% | 11.1% | · | 13.4% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B |
| Margem Bruta % | 35.1% | — | — | — | — |
| Margem Operacional % | -18.6% | — | — | — | — |
| Lucro líquido | $-3.51B | $-634M | $55M | $2.08B | $-1.27B |
| EPS Diluído | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 1.0 | — | — | — | — |
| Índice de liquidez corrente | 1.4 | — | — | — | — |
| Índice de Liquidez Seca | 0.6 | — | — | — | — |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $1.94B | — | — | — | — |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 1.132 declarantes · $12.6B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 107 (-46 vs trimestre anterior) | 87 (-1 vs trimestre anterior) | 360 (+22 vs trimestre anterior) | 313 (+7 vs trimestre anterior) | +106.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.590.154.649 | 127.723.265 | 12,66% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.207.625.391 | 76.046.939 | 9,61% | Ações |
| Davis Selected Advisers | $1.194.789.797 | 75.232.254 | 9,51% | Ações |
| FMR LLC | $992.936.353 | 62.527.478 | 7,90% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $861.999.430 | 54.282.080 | 6,86% | Ações |
| STATE STREET CORP | $842.743.041 | 53.069.461 | 6,71% | Ações |
| Rubric Capital Management LP | $542.599.639 | 34.168.743 | 4,32% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $458.542.313 | 28.931.625 | 3,65% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $425.986.168 | 26.825.324 | 3,39% | Ações |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $320.873.980 | 20.206.170 | 2,55% | Ações |
| AMERIPRISE FINANCIAL INC | $294.863.935 | 18.568.141 | 2,35% | Ações |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $156.853.255 | 9.877.409 | 1,25% | Ações |
| GOLDMAN SACHS GROUP INC | $138.959.750 | 8.750.614 | 1,11% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $132.934.942 | 8.371.218 | 1,06% | Ações |
| Callodine Capital Management, LP | $127.051.783 | 8.000.742 | 1,01% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $103.910.383 | 6.543.475 | 0,83% | Ações |
| Qube Research & Technologies Ltd | $98.141.941 | 6.180.223 | 0,78% | Ações |
| Nantahala Capital Management, LLC | $79.400.000 | 5.000.000 | 0,63% | Opção de compra |
| Assenagon Asset Management S.A. | $79.225.415 | 4.989.006 | 0,63% | Ações |
| AMERICAN CENTURY COMPANIES INC | $73.760.258 | 4.644.851 | 0,59% | Ações |
| FRANKLIN RESOURCES INC | $73.433.026 | 4.624.246 | 0,58% | Ações |
| Gotham Asset Management, LLC | $69.469.966 | 4.374.683 | 0,55% | Ações |
| Brandywine Global Investment Management, LLC | $67.528.501 | 5.423.976 | 0,54% | Ações |
| NORGES BANK | $60.705.175 | 3.822.744 | 0,48% | Ações |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $59.326.092 | 3.735.900 | 0,47% | Ações |
| BlackRock, Inc. | $50.770.853 | 3.197.157 | 0,40% | Ações |
| RHUMBLINE ADVISERS | $45.614.656 | 2.872.464 | 0,36% | Ações |
| Vanguard Global Advisers, LLC | $42.862.486 | 2.699.149 | 0,34% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $42.610.407 | 2.683.275 | 0,34% | Ações |
| FLPUTNAM INVESTMENT MANAGEMENT CO | $42.249.391 | 2.660.541 | 0,34% | Ações |
| California Public Employees Retirement System | $40.629.123 | 2.558.509 | 0,32% | Ações |
| ARGENT CAPITAL MANAGEMENT LLC | $40.499.641 | 2.550.355 | 0,32% | Ações |
| DME Capital Management, LP | $39.761.614 | 2.503.880 | 0,32% | Ações |
| Pictet Asset Management Holding SA | $39.481.647 | 2.437.987 | 0,31% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $37.396.986 | 2.354.974 | 0,30% | Ações |
| Swiss National Bank | $37.102.064 | 2.336.402 | 0,30% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $34.474.638 | 2.170.947 | 0,27% | Ações |
| FIL Ltd | $33.643.336 | 2.118.598 | 0,27% | Ações |
| Robeco Institutional Asset Management B.V. | $33.037.834 | 2.080.468 | 0,26% | Ações |
| BARCLAYS PLC | $32.535.722 | 2.048.849 | 0,26% | Ações |
| Allianz Asset Management GmbH | $32.188.236 | 2.026.967 | 0,26% | Ações |
| Legal & General Group Plc | $31.446.226 | 1.980.241 | 0,25% | Ações |
| BANK OF NOVA SCOTIA | $28.130.467 | 1.771.440 | 0,22% | Ações |
| SEI INVESTMENTS CO | $28.129.290 | 1.771.366 | 0,22% | Ações |
| BANK OF AMERICA CORP /DE/ | $28.053.767 | 1.766.610 | 0,22% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $27.953.373 | 1.760.288 | 0,22% | Ações |
| TORONTO DOMINION BANK | $27.612.303 | 1.738.810 | 0,22% | Ações |
| Invenomic Capital Management LP | $27.611.985 | 1.738.790 | 0,22% | Ações |
| Bridgewater Associates, LP | $26.969.655 | 1.698.341 | 0,21% | Ações |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $26.265.777 | 1.944.173 | 0,21% | Ações |
| RAYMOND JAMES FINANCIAL INC | $24.676.772 | 1.553.953 | 0,20% | Ações |
| Camber Capital Management LP | $24.557.500 | 2.750.000 | 0,20% | Ações |
| Arnhold LLC | $23.200.267 | 1.460.974 | 0,18% | Ações |
| MANNING & NAPIER ADVISORS LLC | $23.136.612 | 1.425.546 | 0,18% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $22.918.445 | 1.443.227 | 0,18% | Ações |
| MOORE CAPITAL MANAGEMENT, LP | $22.718.786 | 1.430.654 | 0,18% | Ações |
| Quantinno Capital Management LP | $21.730.727 | 1.368.433 | 0,17% | Ações |
| Quaker Capital Investments, LLC | $21.567.486 | 1.358.154 | 0,17% | Ações |
| MOORE CAPITAL MANAGEMENT, LP | $21.126.752 | 1.330.400 | 0,17% | Opção de venda |
| STATE OF WISCONSIN INVESTMENT BOARD | $20.950.929 | 1.319.328 | 0,17% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $20.773.000 | 1.308.106 | 0,17% | Ações |
| Man Group plc | $20.719.636 | 1.304.763 | 0,16% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $19.978.215 | 1.258.074 | 0,16% | Ações |
| Caption Management, LLC | $19.850.000 | 1.250.000 | 0,16% | Opção de venda |
| Monaco Asset Management SAM | $19.287.419 | 1.214.573 | 0,15% | Ações |
| UBS Group AG | $18.638.340 | 1.173.699 | 0,15% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $18.213.709 | 1.348.165 | 0,15% | Ações |
| ARCADIA INVESTMENT MANAGEMENT CORP/MI | $17.959.195 | 1.329.326 | 0,14% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $17.915.228 | 1.128.163 | 0,14% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.890.408 | 1.126.600 | 0,14% | Opção de compra |
| HIGHLAND PEAK CAPITAL, LLC | $17.495.488 | 1.101.731 | 0,14% | Ações |
| THOMPSON INVESTMENT MANAGEMENT, INC. | $17.330.906 | 1.091.367 | 0,14% | Ações |
| ALLIANCEBERNSTEIN L.P. | $16.660.991 | 1.233.234 | 0,13% | Ações |
| Bastion Asset Management Inc. | $16.191.713 | 1.052.647 | 0,13% | Ações |
| QSM Asset Management Ltd | $15.898.267 | 996.132 | 0,13% | Ações |
| TD Asset Management Inc | $15.844.127 | 997.741 | 0,13% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $15.495.783 | 975.805 | 0,12% | Ações |
| Sio Capital Management, LLC | $15.154.268 | 954.299 | 0,12% | Ações |
| PRUDENTIAL FINANCIAL INC | $13.466.796 | 848.035 | 0,11% | Ações |
| Illinois Municipal Retirement Fund | $13.448.693 | 846.895 | 0,11% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $13.398.528 | 843.736 | 0,11% | Ações |
| LEVIN CAPITAL STRATEGIES, L.P. | $13.365.809 | 841.676 | 0,11% | Ações |
| Woodline Partners LP | $12.753.911 | 803.143 | 0,10% | Ações |
| HSBC HOLDINGS PLC | $12.656.884 | 797.033 | 0,10% | Ações |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $12.545.248 | 790.003 | 0,10% | Ações |
| CONTINENTAL ADVISORS LLC | $12.430.070 | 782.750 | 0,10% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $11.932.326 | 751.406 | 0,09% | Ações |
| Miller Value Partners, LLC | $11.642.644 | 733.164 | 0,09% | Ações |
| ALGERT GLOBAL LLC | $11.559.052 | 727.900 | 0,09% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.509.824 | 724.800 | 0,09% | Opção de venda |
| VestGen Advisors, LLC | $11.228.726 | 707.099 | 0,09% | Ações |
| Atom Investors LP | $11.206.246 | 705.683 | 0,09% | Ações |
| STOREBRAND ASSET MANAGEMENT AS | $10.891.425 | 685.858 | 0,09% | Ações |
| APG Asset Management N.V. | $10.865.473 | 782.273 | 0,09% | Ações |
| MARSHALL WACE, LLP | $10.826.793 | 681.788 | 0,09% | Ações |
| LPL Financial LLC | $10.767.536 | 678.057 | 0,09% | Ações |
| Poehling Capital Management, INC. | $10.675.322 | 672.250 | 0,08% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $10.620.957 | 668.826 | 0,08% | Ações |
| CITADEL ADVISORS LLC | $10.496.680 | 661.000 | 0,08% | Opção de compra |
| Sound Income Strategies, LLC | $10.242.156 | 644.972 | 0,08% | Ações |
Executivos da empresa 31 insiders · 14 diretores · 20 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Scott Andrew Smith | Chief Executive Officer | 6 de Março de 2026 A | 1.329.326 | 0 | 0 | $0 |
| Michael Goettler | Chief Executive Officer | 4 de Março de 2023 M | 321.653 | 0 | 0 | $0 |
| Campbell Paul | Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller | 25 de Junho de 2026 S | 316.212 | 0 | 2 | $-1.093.257 |
| Theodora Mistras | Chief Financial Officer | 6 de Março de 2026 A | 70.645 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial Officer | 4 de Março de 2023 M | 73.877 | 0 | 0 | $0 |
| Anthony Mauro | President, Developed Markets | 13 de Março de 2024 S | 243.044 | 0 | 0 | $0 |
| Xiangyang (Sean) Ni | President, Greater China | 4 de Março de 2024 A | 90.804 | 0 | 0 | $0 |
| Andrew Cuneo | President, JANZ (Japan, Australia and New Zealand) and Emerging Markets | 4 de Março de 2024 A | 60.055 | 0 | 0 | $0 |
| Menassie Taddese | President, Emerging Markets | 27 de Maio de 2022 S | 0 | 0 | 0 | $0 |
| Andrew Enrietti | Chief Administrative and Transformation Officer | 15 de Agosto de 2026 M | 234.444 | 0 | 0 | $0 |
| Corinne Le Goff | Chief Commercial Officer | 15 de Abril de 2026 M | 107.135 | 0 | 1 | $-72.078 |
| Matthew Joseph Maletta | Chief Legal Officer | 6 de Março de 2026 A | — | 0 | 0 | $0 |
| Brian Roman | Chief Legal Officer | 6 de Março de 2025 A | 193.916 | 0 | 0 | $0 |
| Robert J Coury | Executive Chairman | 4 de Março de 2023 M | 1.174.515 | 0 | 0 | $0 |
| Leo Frans Groothuis | Conselheiro | 30 de Junho de 2026 A | 63.437 | 0 | 0 | $0 |
| David S Simmons | Conselheiro | 30 de Junho de 2026 A | 23.344 | 2 | 0 | $5.202 |
| Richard A Mark | Conselheiro | 6 de Março de 2026 A | 116.145 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Conselheiro | 6 de Março de 2026 A | 46.526 | 0 | 0 | $0 |
| Michael Severino | Conselheiro | 6 de Março de 2026 A | 26.031 | 0 | 0 | $0 |
| Dillon Joellen Lyons | Conselheiro | 6 de Março de 2026 A | 102.526 | 0 | 0 | $0 |
| Mark W Parrish | Conselheiro | 6 de Março de 2026 A | 165.230 | 0 | 0 | $0 |
| Elisha W Finney | Conselheiro | 6 de Março de 2026 A | 62.667 | 0 | 0 | $0 |
| Frank A Damelio | Conselheiro | 6 de Março de 2026 A | 26.031 | 0 | 0 | $0 |
| Don W Cornwell | Conselheiro | 6 de Março de 2026 A | 112.044 | 0 | 0 | $0 |
| Melina E Higgins | Conselheiro | 6 de Março de 2026 A | 146.048 | 0 | 0 | $0 |
| James M Kilts | Conselheiro | 6 de Março de 2026 A | 161.257 | 0 | 0 | $0 |
| Rajiv Malik | Conselheiro | 6 de Março de 2025 A | 1.068.262 | 0 | 0 | $0 |
| Harry Korman | Conselheiro | 6 de Março de 2025 A | 113.937 | 0 | 0 | $0 |
| Mohr Pauline Van Der Meer | Conselheiro | 4 de Março de 2023 M | 40.245 | 0 | 0 | $0 |
| Ian C Read | Conselheiro | 21 de Março de 2022 M | 14.497 | 0 | 0 | $0 |
| Neil F Dimick | Conselheiro | 21 de Março de 2022 M | 75.200 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 159 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| DUSA · Davis Fundamental ETF Trust | 4,97% | 3.855.281 NS | 30 de Abril de 2026 | N-PORT |
| ADPV · Series Portfolios Trust | 4,11% | 471.687 NS | 30 de Abril de 2026 | N-PORT |
| IHE · iShares Trust | 4,05% | 4.225.659 SH | 19 de Agosto de 2026 | Diário |
| DWLD · Davis Fundamental ETF Trust | 4,01% | 1.522.109 NS | 30 de Abril de 2026 | N-PORT |
| LBAY · Tidal Trust I | 3,80% | 41.162 NS | 31 de Maio de 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,47% | 801.373 SH | 19 de Agosto de 2026 | Diário |
| LYLD · Cambria ETF Trust | 2,12% | 8.544 NS | 30 de Abril de 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,08% | 125.516 NS | 30 de Abril de 2026 | N-PORT |
| ABIG · EA Series Trust | 1,97% | 67.399 NS | 29 de Maio de 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,60% | 260.113 SH | 19 de Agosto de 2026 | Diário |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,53% | 749.279 SH | 19 de Agosto de 2026 | Diário |
| PILL · Direxion Shares ETF Trust | 1,43% | 12.352 NS | 30 de Abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,25% | 64.442 SH | 19 de Agosto de 2026 | Diário |
| RPV · Invesco Exchange-Traded Fund Trust | 1,11% | 1.186.633 SH | 19 de Agosto de 2026 | Diário |
| SYLD · Cambria ETF Trust | 1,03% | 662.665 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,94% | 42.565 NS | 31 de Maio de 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 0,88% | 103.740 SH | 19 de Agosto de 2026 | Diário |
| WBIG · Absolute Shares Trust | 0,72% | 12.370 NS | 30 de Junho de 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,71% | 6.483.864 NS | 30 de Abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,69% | 59.415 SH | 19 de Agosto de 2026 | Diário |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,66% | 251.956 NS | 31 de Maio de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,65% | 7.904.043 NS | 30 de Abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,65% | 20.246 NS | 30 de Abril de 2026 | N-PORT |
| CVY · Invesco Exchange-Traded Fund Trust | 0,64% | 48.771 SH | 19 de Agosto de 2026 | Diário |
| AUSF · Global X Funds | 0,55% | 287.430 NS | 31 de Maio de 2026 | N-PORT |
| ITAN · EA Series Trust | 0,51% | 27.790 NS | 29 de Maio de 2026 | N-PORT |
| ABCS · EA Series Trust | 0,50% | 3.459 NS | 29 de Maio de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,44% | 184.557 NS | 30 de Abril de 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 117.672 NS | 30 de Abril de 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 0,40% | 24.403 NS | 30 de Abril de 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,39% | 16.955.526 SH | 19 de Agosto de 2026 | Diário |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,37% | 2.917.765 NS | 31 de Maio de 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,35% | 10.490.000 | 19 de Agosto de 2026 | Diário |
| SCHM · SCHWAB STRATEGIC TRUST | 0,35% | 3.114.448 NS | 31 de Maio de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 466.740 NS | 30 de Abril de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,33% | 1.672.565 NS | 30 de Abril de 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 91.932 NS | 30 de Abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,30% | 685.998 SH | 19 de Agosto de 2026 | Diário |
| VFVA · VANGUARD WELLINGTON FUND | 0,28% | 150.960 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,28% | 530.957 NS | 30 de Abril de 2026 | N-PORT |
| RXL · ProShares Trust | 0,27% | 12.010 NS | 31 de Maio de 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,27% | 67.551 NS | 31 de Maio de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,27% | 3.499.976 SH | 19 de Agosto de 2026 | Diário |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 115.598 SH | 19 de Agosto de 2026 | Diário |
| REVS · Columbia ETF Trust I | 0,26% | 49.318 NS | 30 de Abril de 2026 | N-PORT |
| ESML · iShares Trust | 0,25% | 451.926 SH | 19 de Agosto de 2026 | Diário |
| SMMD · iShares Trust | 0,25% | 588.860 SH | 19 de Agosto de 2026 | Diário |
| IMCV · iShares Trust | 0,25% | 182.951 SH | 19 de Agosto de 2026 | Diário |
| CURE · Direxion Shares ETF Trust | 0,25% | 22.967 NS | 30 de Abril de 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 115.075 NS | 30 de Abril de 2026 | N-PORT |